Avtor/Urednik		Žagar, Ivana; Mitrović, Svetlana; Han, Ruben
Naslov		Scintigrafija tumora neuroektoderma sa 131-I-meta-jodo-benzilgvanidinom (131-I-mIBG)
Prevedeni naslov		Scintigraphic evaluation of neural crest tumors with 131-I-meta-iodo-benzylguanidine (131-I-mIBG)
Tip		članek
Vir		Radiološki arhiv
Vol. in št.		Letnik 3, št. 5
Leto izdaje		1994
Obseg		str. 463-8
Jezik		eng
Abstrakt		Whole-body sequential scintigraphies with 131I-meta-iodobezylguaninine (131I-mIBG), were performed in 18 patients with pheochromocytoma. 2 with paraganglioma. 2 patients with malignant insulinoma one with carcinoid, 2 patients with medullary thyroid carcinoma and in 49 children with neuroblastoma. the uptake of 131 I-mIBG was calculated from the activity measured prior and after the application and acquired images and was expressed as the percent of the administered dose. Myocardial and salivary gland uptake were estimated semiquantitatively, according to the method of Nakajo. The following siteswere correctly demonstrated: primary site in 14/14 pheochromocytoma patients and 31/33 neuroblastoma patients, metastases in one pheochromocytoma, 2 malignant isulinoma and 30 neuroblastoma patients. MIBG scintigraphy findings confirmed clinical remission of the disease in 2 patients with pheochromocytoma, one with carcinoid and in 15 neuroblastoma patients. Mean values (and range) of mIBG uptake in lesions were: in pheochromocytoma 3.95% (0.1-15), in primary neuroblastoma sites 0.7% (0.05-1.92) and in neuroblastoma metastases 0.12% (0.002-0.83). In patients who developed bonemarrow involvement, myocardial and primary tumor uptake diminished. (Abstract truncated at 2000 characters)
Deskriptorji		NEUROECTODERMAL TUMORS NEUROBLASTOMA PHEOCHROMOCYTOMA IODINE RADIOISOTOPES BENZYL COMPOUNDS